FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Olanzapine and Fluoxetine (Symbyax) Capsules
Status: Discontinuation
»Therapeutic Categories: Psychiatry

Eli Lilly and Co. (New 09/25/2017)

Company Contact Information:

Presentation Posting Date Related Information
Olanzapine/Fluoxetine 12mg/25mg (NDC 0002-3232-30) 09/25/2017 Discontinuation of the manufacture of the drug. This discontinuation is not related to safety or efficacy of drug. Four additional approved doses of Symbyax continue to be available the US market.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English